ALK boss on deficit: Investments in the future require short-term costs

The revenue of Danish allergy group ALK has increased to approximately DKK 3 billion (USD 460 million), however, the bottom line and EBIT remain negative. Despite red numbers, ALK increase investments in the coming year. "ALK is a growth case, and it also entails short-term costs," says the CEO.

Photo: /Ritzau Scanpix/Niels Ahlmann Olesen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles